Monopar Therapeutics Files 8-K

Ticker: MNPR · Form: 8-K · Filed: 2025-09-15T00:00:00.000Z

Sentiment: neutral

Topics: corporate-filing, 8-k

TL;DR

Monopar Therapeutics filed a routine 8-K on 9/15/25, no major news.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on September 15, 2025, reporting on its corporate activities. The filing indicates no specific material events or financial updates were disclosed in this particular report, suggesting it may be a routine filing or related to administrative matters.

Why It Matters

This filing serves as a public record of corporate events for Monopar Therapeutics, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K with no disclosed material events, indicating no immediate new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Monopar Therapeutics?

This 8-K filing by Monopar Therapeutics on September 15, 2025, is a current report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

What is Monopar Therapeutics' state of incorporation?

Monopar Therapeutics Inc. is incorporated in Delaware.

What is the address of Monopar Therapeutics' principal executive offices?

The principal executive offices of Monopar Therapeutics are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

What is the telephone number for Monopar Therapeutics?

Monopar Therapeutics' telephone number, including area code, is (847) 388-0349.

Does this filing disclose any specific material events or financial statements?

Based on the provided text, this filing is a Form 8-K, but it does not detail specific material events or financial statements. It lists 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as items of information, but the content of these is not provided.

From the Filing

0001437749-25-029005.txt : 20250915 0001437749-25-029005.hdr.sgml : 20250915 20250915070011 ACCESSION NUMBER: 0001437749-25-029005 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 32 CONFORMED PERIOD OF REPORT: 20250915 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250915 DATE AS OF CHANGE: 20250915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 251313146 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20250912_8k.htm FORM 8-K mnpr20250912_8k.htm false 0001645469 0001645469 2025-09-15 2025-09-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 15, 2025   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 7.01   Regulation FD Disclosure.     On September 14, 2025, Monopar Therapeutics Inc. ("Monopar " ) issued a press release announcing the presentation of new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025.   The press release, poster presentation and oral presentation are furnished as Exhibit 99.1, 99.2 and 99.3, respectively, and incorporated herein by reference.   Item 9.01 Fi

View on Read The Filing